# Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> **NCT04852822** · — · TERMINATED · sponsor: **University of Washington** · enrollment: 350 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Electronic Health Record Review

## Key facts

- **NCT ID:** NCT04852822
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-18
- **Primary completion:** 2023-01-01
- **Final completion:** 2024-07-01
- **Target enrollment:** 350 (ACTUAL)
- **Why stopped:** The study ended earlier than anticipated due to slow accrual.
- **Last updated:** 2024-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04852822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04852822, "Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04852822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*